{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:01:24Z","timestamp":1783573284218,"version":"3.55.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose of Review<\/jats:title>\n                <jats:p>The treatment strategy for <jats:italic>BRAF<\/jats:italic>-mutated melanoma remains unsatisfactory, although the advent of immune checkpoint inhibition has improved the prognosis of advanced melanoma. This article reports current evidence on the efficacy and safety of sequential immunotherapy with targeted therapy in patients with <jats:italic>BRAF<\/jats:italic>-mutated melanoma. It discusses criteria for the use of available options in clinical practice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>Targeted therapy provides rapid disease control in a relatively high proportion of patients, although the development of secondary resistance limits the duration of responses; in contrast, immunotherapy may induce slow but more durable responses in a subset of patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>Therefore, the identification of a combination strategy for the use of these therapies seems a promising perspective. Currently, inconsistent data have been obtained, but most studies indicate that the administration of BRAFi\/MEKi prior to immune checkpoint inhibitors appears to reduce the efficacy of immunotherapy. On the contrary, several clinical and real-life studies suggest that frontline immunotherapy with subsequent targeted therapy may be associated with better tumor control than immunotherapy alone. Larger clinical studies are ongoing to confirm the efficacy and safety of this sequencing strategy for treating <jats:italic>BRAF<\/jats:italic>-mutated melanoma with immunotherapy followed by targeted therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11912-023-01402-8","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T09:02:58Z","timestamp":1680166978000},"page":"623-634","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5677-5679","authenticated-orcid":false,"given":"Claudia","family":"Trojaniello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Sparano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Cioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Antonio","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,30]]},"reference":[{"key":"1402_CR1","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1200\/EDBK_243071","volume":"39","author":"AC Pavlick","year":"2019","unstructured":"Pavlick AC, Fecher L, Ascierto PA, Sullivan RJ. Frontline therapy for BRAF-mutated metastatic melanoma: how do you choose, and is there one correct answer? Am Soc Clin Oncol Educ Book. 2019;39:564\u201371. https:\/\/doi.org\/10.1200\/EDBK_243071.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"26","key":"1402_CR2","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O\u2019Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1103782.","journal-title":"N Engl J Med"},{"issue":"1","key":"1402_CR3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin AM, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1412690.","journal-title":"N Engl J Med"},{"key":"1402_CR4","unstructured":"Dabrafenib and trametinib followed by ipilimumab and nivolumab or ipilimumab and nivolumab followed by dabrafenib and trametinib in treating patients with stage III-IV BRAFV600 melanoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02224781"},{"key":"1402_CR5","unstructured":"Sequential Combo Immuno and Target Therapy (SECOMBIT) Study (SECOMBIT). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02631447"},{"key":"1402_CR6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02961","author":"PA Ascierto","year":"2022","unstructured":"Ascierto PA, Mandal\u00e0 M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V, Arance A, Guida M, Maiello E, Gogas H, Richtig E, Fierro MT, Lebb\u00e8 C, Helgadottir H, Queirolo P, Spagnolo F, Tucci M, Del Vecchio M, Gonzales Cao M, Minisini AM, De Placido S, Sanmamed MF, Mallardo D, Curvietto M, Melero I, Palmieri G, Grimaldi AM, Giannarelli D, Dummer R, Chiarion Sileni V. Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated BRAF-mutated metastatic melanoma (SECOMBIT): a randomized, three-arm, open-label phase II trial. J Clin Oncol. 2022. https:\/\/doi.org\/10.1200\/JCO.21.02961. (Online ahead of print).","journal-title":"J Clin Oncol"},{"key":"1402_CR7","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ejca.2017.06.028","volume":"83","author":"S Ugurel","year":"2017","unstructured":"Ugurel S, R\u00f6hmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Long GV, Lorigan P, McArthur GA, Ribas A, Robert C, Schadendorf D, Garbe C. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Eur J Cancer. 2017;83:247\u201357. https:\/\/doi.org\/10.1016\/j.ejca.2017.06.028.","journal-title":"Eur J Cancer"},{"key":"1402_CR8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.phrs.2018.08.019","volume":"136","author":"M Kuske","year":"2018","unstructured":"Kuske M, Westphal D, Wehner R, Schmitz M, Beissert S, Praetorius C, Meier F. Immunomodulatory effects of BRAF and MEK inhibitors: implications for melanoma therapy. Pharmacol Res. 2018;136:151\u20139. https:\/\/doi.org\/10.1016\/j.phrs.2018.08.019.","journal-title":"Pharmacol Res"},{"issue":"14","key":"1402_CR9","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1056\/NEJMc1302338","volume":"368","author":"A Ribas","year":"2013","unstructured":"Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med. 2013;368(14):1365\u20136. https:\/\/doi.org\/10.1056\/NEJMc1302338.","journal-title":"N Engl J Med"},{"issue":"5","key":"1402_CR10","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/pcmr.12383","volume":"28","author":"DR Minor","year":"2015","unstructured":"Minor DR, Puzanov I, Callahan MK, Hug BA, Hoos A. Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab. Pigment Cell Melanoma Res. 2015;28(5):611\u20132. https:\/\/doi.org\/10.1111\/pcmr.12383.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"6","key":"1402_CR11","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/s41591-019-0474-7","volume":"25","author":"RJ Sullivan","year":"2019","unstructured":"Sullivan RJ, Hamid O, Gonzalez R, Infante JR, Patel MR, Hodi FS, Lewis KD, Tawbi HA, Hernandez G, Wongchenko MJ, Chang Y, Roberts L, Ballinger M, Yan Y, Cha E, Hwu P. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nat Med. 2019;25(6):929\u201335. https:\/\/doi.org\/10.1038\/s41591-019-0474-7.","journal-title":"Nat Med"},{"key":"1402_CR12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejca.2021.09.011","volume":"158","author":"L Zimmer","year":"2021","unstructured":"Zimmer L, Livingstone E, Krackhardt A, Schultz ES, G\u00f6ppner D, Assaf C, Trebing D, Stelter K, Windemuth-Kieselbach C, Ugurel S, Schadendorf D. Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial. Eur J Cancer. 2021;158:72\u201384. https:\/\/doi.org\/10.1016\/j.ejca.2021.09.011.","journal-title":"Eur J Cancer"},{"issue":"2","key":"1402_CR13","doi-asserted-by":"publisher","first-page":"e001806","DOI":"10.1136\/jitc-2020-001806","volume":"8","author":"PF Ferrucci","year":"2020","unstructured":"Ferrucci PF, Di Giacomo AM, Del Vecchio M, Atkinson V, Schmidt H, Schachter J, Queirolo P, Long GV, Stephens R, Svane IM, Lotem M, Abu-Amna M, Gasal E, Ghori R, Diede SJ, Croydon ES, Ribas A, Ascierto PA, KEYNOTE-022 international team. KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. J Immunother Cancer. 2020;8(2):e001806. https:\/\/doi.org\/10.1136\/jitc-2020-001806.","journal-title":"J Immunother Cancer"},{"issue":"10240","key":"1402_CR14","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","volume":"395","author":"R Gutzmer","year":"2020","unstructured":"Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, Pereira RP, Eigentler T, Rutkowski P, Demidov L, Manikhas GM, Yan Y, Huang KC, Uyei A, McNally V, McArthur GA, Ascierto PA. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;395(10240):1835\u201344. https:\/\/doi.org\/10.1016\/S0140-6736(20)30934-X.","journal-title":"Lancet"},{"key":"1402_CR15","doi-asserted-by":"publisher","first-page":"S1172","DOI":"10.1016\/j.annonc.2020.08.2273","volume":"31","author":"P Nathan","year":"2020","unstructured":"Nathan P, Dummer R, Long GV, Ascierto PA, Tawbi HA, Robert C, Rutkowski P, Leonov O, Dutriaux C, Mandala M, Lorigan P, Ferrucci PF, Flaherty KT, Brase JC, Green S, Haas T, Masood A, Gasal E, Ribas A, Schadendorf A. LBA43 spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: results from the randomized part 3 of the phase III COMBI-i trial. Ann Oncol. 2020;31:S1172.","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"1402_CR16","doi-asserted-by":"publisher","first-page":"9520","DOI":"10.1200\/JCO.2021.39.15_suppl.9520","volume":"39","author":"EM Burton","year":"2021","unstructured":"Burton EM, Amaria RN, Glitza IC, Milton DR, Diab A, Patel SP, McQuade JL, Honaker V, Wong MKK, Hwu P, Wargo JA, Davies MA, Tawbi HAH. Phase II study of TRIplet combination Nivolumab (N) with Dabrafenib (D) and Trametinib (T) (TRIDeNT) in patients (pts) with PD-1 na\u00efve or refractory BRAF-mutated metastatic mela- noma (MM) with or without active brain metastases. J Clin Oncol. 2021;39(15_suppl):9520.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1402_CR17","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","volume":"19","author":"FS Hodi","year":"2018","unstructured":"Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, Lao CD, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hill A, Hogg D, Marquez-Rodas I, Jiang J, Rizzo J, Larkin J, Wolchok JD. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(11):1480\u201392. https:\/\/doi.org\/10.1016\/S1470-2045(18)30700-9.","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"1402_CR18","doi-asserted-by":"publisher","first-page":"9503","DOI":"10.1200\/JCO.2021.39.15_suppl.9503","volume":"39","author":"EJ Lipson","year":"2021","unstructured":"Lipson EJ, Tawbi HA-H, Schadendorf D, Ascierto PA, Matamala L, Guti\u00e9rrez EC, Rutkowski P, Gogas H, Lao CD, de Menezes JJ, Dalle S, Arance AM, Grob JJ, Srivastava S, Abaskharoun M, Simonsen KL, Li B, Long GV, Hodi FS. Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: primary phase III results from RELATIVITY-047 (CA224\u2013047). J Clin Oncol. 2021;39(15_suppl):9503.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1402_CR19","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/S1470-2045(22)00452-1","volume":"23","author":"R Dummer","year":"2022","unstructured":"Dummer R, Queirolo P, Abajo Guijarro AM, Hu Y, Wang D, de Azevedo SJ, Robert C, Ascierto PA, Chiarion-Sileni V, Pronzato P, Spagnolo F, Mujika Eizmendi K, Liszkay G, de la Cruz ML, Tawbi H. Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2022;23(9):1145\u201355.","journal-title":"Lancet Oncol"},{"issue":"19","key":"1402_CR20","doi-asserted-by":"publisher","first-page":"388","DOI":"10.21037\/atm.2017.06.47","volume":"5","author":"N Karachaliou","year":"2017","unstructured":"Karachaliou N, Gonzalez-Cao M, Sosa A, Berenguer J, Bracht JWP, Ito M, Rosell R. The combination of checkpoint immunotherapy and targeted therapy in cancer. Ann Transl Med. 2017;5(19):388. https:\/\/doi.org\/10.21037\/atm.2017.06.47.","journal-title":"Ann Transl Med"},{"key":"1402_CR21","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350\u20135. https:\/\/doi.org\/10.1126\/science.aar4060.","journal-title":"Science"},{"key":"1402_CR22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.coi.2015.12.006","volume":"39","author":"PK Lau","year":"2016","unstructured":"Lau PK, Ascierto PA, McArthur G. Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition. Curr Opin Immunol. 2016;39:30\u20138. https:\/\/doi.org\/10.1016\/j.coi.2015.12.006.","journal-title":"Curr Opin Immunol"},{"issue":"13","key":"1402_CR23","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(15)00087-X","volume":"16","author":"JJ Grob","year":"2015","unstructured":"Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, Stroyakovskiy D, Drucis K, Grange F, Chiarion-Sileni V, Rutkowski P, Lichinitser M, Levchenko E, Wolter P, Hauschild A, Long GV, Nathan P, Ribas A, Flaherty K, Sun P, Legos JJ, McDowell DO, Mookerjee B, Schadendorf D, Robert C. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol. 2015;16(13):1389\u201398. https:\/\/doi.org\/10.1016\/S1470-2045(15)00087-X.","journal-title":"Lancet Oncol"},{"issue":"36","key":"1402_CR24","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1200\/JCO.21.02659","volume":"40","author":"R Dummer","year":"2022","unstructured":"Dummer R, Flaherty KT, Robert C, Arance A, de Groot JWB, Garbe C, Gogas HJ, Gutzmer R, Krajsov\u00e1 I, Liszkay G, Loquai C, Mandal\u00e0 M, Schadendorf D, Yamazaki N, di Pietro A, Cantey-Kiser J, Edwards M, Ascierto PA. COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. J Clin Oncol. 2022;40(36):4178\u201388. https:\/\/doi.org\/10.1200\/JCO.21.02659.","journal-title":"J Clin Oncol"},{"issue":"19","key":"1402_CR25","doi-asserted-by":"publisher","first-page":"5225","DOI":"10.1158\/1078-0432.CCR-21-0809","volume":"27","author":"PA Ascierto","year":"2021","unstructured":"Ascierto PA, Dr\u00e9no B, Larkin J, Ribas A, Liszkay G, Maio M, Mandal\u00e0 M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Atkinson V, Dutriaux C, Garbe C, Hsu J, Jones S, Li H, McKenna E, Voulgari A, McArthur GA. 5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation-positive advanced melanoma: extended follow-up of the coBRIM study. Clin Cancer Res. 2021;27(19):5225\u201335. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0809.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1402_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s12094-016-1514-0","volume":"19","author":"F Aya","year":"2017","unstructured":"Aya F, Fernandez-Martinez A, Gaba L, Victoria I, Tosca M, Pineda E, Gascon P, Prat A, Arance A. Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma. Clin Transl Oncol. 2017;19(1):119\u201324. https:\/\/doi.org\/10.1007\/s12094-016-1514-0.","journal-title":"Clin Transl Oncol"},{"issue":"10","key":"1402_CR27","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11864-016-0427-z","volume":"17","author":"M Ratterman","year":"2016","unstructured":"Ratterman M, Hallmeyer S, Richards J. Sequencing of new and old therapies for metastatic melanoma. Curr Treat Options Oncol. 2016;17(10):52. https:\/\/doi.org\/10.1007\/s11864-016-0427-z.","journal-title":"Curr Treat Options Oncol"},{"issue":"12","key":"1402_CR28","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1016\/S1470-2045(16)30578-2","volume":"17","author":"GV Long","year":"2016","unstructured":"Long GV, Grob JJ, Nathan P, Ribas A, Robert C, Schadendorf D, Lane SR, Mak C, Legenne P, Flaherty KT, Davies MA. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol. 2016;17(12):1743\u201354. https:\/\/doi.org\/10.1016\/S1470-2045(16)30578-2.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1402_CR29","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.annonc.2020.07.004","volume":"31","author":"U Keilholz","year":"2020","unstructured":"Keilholz U, Ascierto PA, Dummer R, Robert C, Lorigan P, van Akkooi A, Arance A, Blank CU, Chiarion Sileni V, Donia M, Faries MB, Gaudy-Marqueste C, Gogas H, Grob JJ, Guckenberger M, Haanen J, Hayes AJ, Hoeller C, Lebb\u00e9 C, Lugowska I, Mandal\u00e0 M, M\u00e1rquez-Rodas I, Nathan P, Neyns B, Olofsson Bagge R, Puig S, Rutkowski P, Schilling B, Sondak VK, Tawbi H, Testori A, Michielin O. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020;31(11):1435\u201348. https:\/\/doi.org\/10.1016\/j.annonc.2020.07.004.","journal-title":"Ann Oncol"},{"issue":"18","key":"1402_CR30","doi-asserted-by":"publisher","first-page":"9890","DOI":"10.3390\/ijms22189890","volume":"22","author":"T Jung","year":"2021","unstructured":"Jung T, Haist M, Kuske M, Grabbe S, Bros M. Immunomodulatory properties of BRAF and MEK inhibitors used for melanoma therapy-paradoxical ERK activation and beyond. Int J Mol Sci. 2021;22(18):9890. https:\/\/doi.org\/10.3390\/ijms22189890.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1402_CR31","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/pcmr.12835","volume":"33","author":"ILM Reijers","year":"2020","unstructured":"Reijers ILM, Rozeman EA, Wilgenhof S, van Thienen JV, Haanen JBAG, Blank CU. Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: a retrospective single-centre experience in patients with BRAF-mutated melanoma. Pigment Cell Melanoma Res. 2020;33(3):498\u2013506. https:\/\/doi.org\/10.1111\/pcmr.12835.","journal-title":"Pigment Cell Melanoma Res"},{"key":"1402_CR32","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/1479-5876-10-107","volume":"10","author":"PA Ascierto","year":"2012","unstructured":"Ascierto PA, Simeone E, Giannarelli D, Grimaldi AM, Romano A, Mozzillo N. Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J Transl Med. 2012;10:107. https:\/\/doi.org\/10.1186\/1479-5876-10-107.","journal-title":"J Transl Med"},{"issue":"4","key":"1402_CR33","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3109\/07357907.2014.885984","volume":"32","author":"PA Ascierto","year":"2014","unstructured":"Ascierto PA, Simeone E, Sileni VC, Del Vecchio M, Marchetti P, Cappellini GC, Ridolfi R, de Rosa F, Cognetti F, Ferraresi V, Testori A, Queirolo P, Bernengo MG, Guida M, Galli L, Mandal\u00e0 M, Cimminiello C, Rinaldi G, Carnevale-Schianca F, Maio M. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program. Cancer Invest. 2014;32(4):144\u20139. https:\/\/doi.org\/10.3109\/07357907.2014.885984.","journal-title":"Cancer Invest"},{"issue":"1","key":"1402_CR34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165(1):35\u201344. https:\/\/doi.org\/10.1016\/j.cell.2016.02.065.","journal-title":"Cell"},{"key":"1402_CR35","doi-asserted-by":"publisher","unstructured":"Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong TG, Moon HH, Davar D, O\u2019Rourke M, Stephenson JJ, Curti BD, Urba WJ, Brell JM, Funchain P, Kendra KL, Ikeguchi AP, Jaslowski A, Bane CL, Taylor MA, Bajaj M, Conry RM, Ellis RJ, Logan TF, Laudi N, Sosman JA, Crockett DG, Pecora AL, Okazaki IJ, Reganti S, Chandra S, Guild S, Chen HX, Streicher HZ, Wolchok JD, Ribas A, Kirkwood JM. Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial-ECOG-ACRIN EA6134. J Clin Oncol. 2022:JCO2201763. https:\/\/doi.org\/10.1200\/JCO.22.01763.","DOI":"10.1200\/JCO.22.01763"},{"issue":"2","key":"1402_CR36","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1200\/JCO.22.01763","volume":"41","author":"MB Atkins","year":"2023","unstructured":"Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong TG, Moon HH, Davar D, O\u2019Rourke M, Stephenson JJ, Curti BD, Urba WJ, Brell JM, Funchain P, Kendra KL, Ikeguchi AP, Jaslowski A, Bane CL, Taylor MA, Bajaj M, Conry RM, Ellis RJ, Logan TF, Laudi N, Sosman JA, Crockett DG, Pecora AL, Okazaki IJ, Reganti S, Chandra S, Guild S, Chen HX, Streicher HZ, Wolchok JD, Ribas A, Kirkwood JM. Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023;41(2):186\u201397. https:\/\/doi.org\/10.1200\/JCO.22.01763.","journal-title":"J Clin Oncol"},{"issue":"Suppl. 4","key":"1402_CR37","doi-asserted-by":"publisher","first-page":"S1173","DOI":"10.1016\/j.annonc.2020.08.2275","volume":"31","author":"PA Ascierto","year":"2020","unstructured":"Ascierto PA, Mandala M, Ferrucci PF, Rutkowski P, Guidoboni M, Arance Fernandez AM, Ferraresi V, Maiello E, Guida M, Del Vecchio M, Fierro MT, Queirolo P, Lebb\u00e9 C, Helgadottir H, Melero I, Palmieri G, Giannarelli D, Grimaldi AM, Dummer R, Chiarion SV. LBA45 First report of efficacy and safety from the phase II study SECOMBIT (Sequential COMBo Immuno and Targeted therapy study). Ann Oncol. 2020;31(Suppl. 4):S1173\u20134.","journal-title":"Ann Oncol"},{"issue":"11","key":"1402_CR38","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1002\/cncr.28620","volume":"120","author":"A Ackerman","year":"2014","unstructured":"Ackerman A, Klein O, McDermott DF, Wang W, Ibrahim N, Lawrence DP, Gunturi A, Flaherty KT, Hodi FS, Kefford R, Menzies AM, Atkins MB, Long GV, Sullivan RJ. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer. 2014;120(11):1695\u2013701. https:\/\/doi.org\/10.1002\/cncr.28620.","journal-title":"Cancer"},{"issue":"3","key":"1402_CR39","doi-asserted-by":"publisher","first-page":"e1283462","DOI":"10.1080\/2162402X.2017.1283462","volume":"6","author":"E Simeone","year":"2017","unstructured":"Simeone E, Grimaldi AM, Festino L, Giannarelli D, Vanella V, Palla M, Curvietto M, Esposito A, Palmieri G, Mozzillo N, Ascierto PA. Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma. Oncoimmunology. 2017;6(3):e1283462. https:\/\/doi.org\/10.1080\/2162402X.2017.1283462.","journal-title":"Oncoimmunology"},{"issue":"Suppl","key":"1402_CR40","doi-asserted-by":"publisher","first-page":"Abstract 9005","DOI":"10.1200\/jco.2015.33.15_suppl.9005","volume":"33","author":"A Daud","year":"2015","unstructured":"Daud A, Ribas A, Robert C, Hodi FS, Wolchok JD, JoshuaWen-Jen Hwu AM, Weber JS, Gangadhar TC, Joseph RW, Dronca RS, Patnaik A, Zarour HM, Kefford R, Lindia JA, Li XN, Ebbinghaus S, Kang SP, Hamid O. Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. J Clin Oncol. 2015;33(Suppl):Abstract 9005.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1402_CR41","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"16","author":"A Ribas","year":"2015","unstructured":"Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O\u2019Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908\u201318. https:\/\/doi.org\/10.1016\/S1470-2045(15)00083-2.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1402_CR42","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1001\/jamaoncol.2020.2288","volume":"6","author":"I Puzanov","year":"2020","unstructured":"Puzanov I, Ribas A, Robert C, Schachter J, Nyakas M, Daud A, Arance A, Carlino MS, O\u2019Day SJ, Long GV, Margolin KA, Dummer R, Schadendorf D, Lutzky J, Ascierto PA, Tarhini A, Lin J, Mogg R, Homet Moreno B, Ibrahim N, Hamid O. Association of BRAF V600E\/K mutation status and prior BRAF\/MEK inhibition with pembrolizumab outcomes in advanced melanoma: pooled analysis of 3 clinical trials. JAMA Oncol. 2020;6(8):1256\u201364. https:\/\/doi.org\/10.1001\/jamaoncol.2020.2288.","journal-title":"JAMA Oncol"},{"issue":"7","key":"1402_CR43","doi-asserted-by":"publisher","first-page":"e004610","DOI":"10.1136\/jitc-2022-004610","volume":"10","author":"I Pires da Silva","year":"2022","unstructured":"Pires da Silva I, Zakria D, Ahmed T, Trojanello C, Dimitriou F, Allayous C, Gerard C, Zimmer L, Lo S, Michielin O, Lebbe C, Mangana J, Ascierto PA, Johnson DB, Carlino M, Menzies A, Long G. Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF\/MEK inhibitors in patients with BRAF mutant metastatic melanoma. J Immunother Cancer. 2022;10(7):e004610. https:\/\/doi.org\/10.1136\/jitc-2022-004610.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"1402_CR44","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/cncr.31889","volume":"125","author":"KR Saab","year":"2019","unstructured":"Saab KR, Mooradian MJ, Wang DY, Chon J, Xia CY, Bialczak A, Abbate KT, Menzies AM, Johnson DB, Sullivan RJ, Shoushtari AN. Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy. Cancer. 2019;125(6):884\u201391. https:\/\/doi.org\/10.1002\/cncr.31889.","journal-title":"Cancer"},{"issue":"1","key":"1402_CR45","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/CJI.0000000000000148","volume":"40","author":"DB Johnson","year":"2017","unstructured":"Johnson DB, Pectasides E, Feld E, Ye F, Zhao S, Johnpulle R, Merritt R, McDermott DF, Puzanov I, Lawrence D, Sosman JA, Buchbinder E, Sullivan RJ. Sequencing treatment in BRAFV600 mutant melanoma: anti-PD-1 before and after BRAF inhibition. J Immunother. 2017;40(1):31\u20135. https:\/\/doi.org\/10.1097\/CJI.0000000000000148.","journal-title":"J Immunother"},{"issue":"5","key":"1402_CR46","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00262-019-02311-1","volume":"68","author":"B Schilling","year":"2019","unstructured":"Schilling B, Martens A, Geukes Foppen MH, Gebhardt C, Hassel JC, Rozeman EA, Gesierich A, Gutzmer R, K\u00e4hler KC, Livingstone E, Diamantopoulos PT, Gogas H, Madonna G, Ascierto PA, Goldinger SM, Mangana J, Garbe C, Schadendorf D, Blank C, Weide B. First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis. Cancer Immunol Immunother. 2019;68(5):765\u201372. https:\/\/doi.org\/10.1007\/s00262-019-02311-1.","journal-title":"Cancer Immunol Immunother"},{"issue":"18","key":"1402_CR47","doi-asserted-by":"publisher","first-page":"7637","DOI":"10.1002\/cam4.2625","volume":"8","author":"JC Moser","year":"2019","unstructured":"Moser JC, Chen D, Hu-Lieskovan S, Grossmann KF, Patel S, Colonna SV, Ying J, Hyngstrom JR. Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with frontline BRAF\/MEK inhibitors, anti-PD-1 antibodies, or nivolumab\/ipilimumab. Cancer Med. 2019;8(18):7637\u201343. https:\/\/doi.org\/10.1002\/cam4.2625.","journal-title":"Cancer Med"},{"issue":"suppl","key":"1402_CR48","doi-asserted-by":"publisher","first-page":"abstr 9532","DOI":"10.1200\/JCO.2018.36.15_suppl.9532","volume":"36","author":"CY Xia","year":"2018","unstructured":"Xia CY, Wang DY, Mason R, Smith JL, McKean MA, Lo S, Guminski AD, Long GV, Carlino MS, Atkinson V, Millward M, McQuade JL, Amaria RN, Johnson DB, Menzies AM. Activity of targeted therapy after failure of first-line immunotherapy in BRAF-mutant metastatic melanoma. J Clin Oncol. 2018;36(suppl):abstr 9532.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1402_CR49","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.3390\/cancers14092082","volume":"14","author":"M Haist","year":"2022","unstructured":"Haist M, Stege H, Ebner R, Fleischer MI, Loquai C, Grabbe S. The role of treatment sequencing with immune-checkpoint inhibitors and BRAF\/MEK inhibitors for response and survival of patients with BRAFV600-mutant metastatic melanoma-a retrospective, real-world cohort study. Cancers (Basel). 2022;14(9):2082. https:\/\/doi.org\/10.3390\/cancers14092082.","journal-title":"Cancers (Basel)"},{"issue":"34","key":"1402_CR50","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1200\/JCO.2017.73.2289","volume":"35","author":"D Schadendorf","year":"2017","unstructured":"Schadendorf D, Wolchok JD, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Chesney J, Robert C, Grossmann K, McDermott D, Walker D, Bhore R, Larkin J, Postow MA. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol. 2017;35(34):3807\u201314. https:\/\/doi.org\/10.1200\/JCO.2017.73.2289.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1402_CR51","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/nrclinonc.2013.153","volume":"10","author":"HL Kaufman","year":"2013","unstructured":"Kaufman HL, Kirkwood JM, Hodi FS, Agarwala S, Amatruda T, Bines SD, Clark JI, Curti B, Ernstoff MS, Gajewski T, Gonzalez R, Hyde LJ, Lawson D, Lotze M, Lutzky J, Margolin K, McDermott DF, Morton D, Pavlick A, Richards JM, Sharfman W, Sondak VK, Sosman J, Steel S, Tarhini A, Thompson JA, Titze J, Urba W, White R, Atkins MB. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013;10(10):588\u201398. https:\/\/doi.org\/10.1038\/nrclinonc.2013.153.","journal-title":"Nat Rev Clin Oncol"},{"key":"1402_CR52","unstructured":"Postow M, Larkin J, Wolchok JD, Chiarion-Sileni V, Hodi FS, Rutkowski P, Grob JJ, Grossmann K, Schadendorf D, Chesney J, Smylie M, Hill A, Robert C, Pavlick AC, Haanen J, McArthur GA, McDermott D, Demelo S, Bhore R, Gonzalez. Pooled 3-year overall survival data from Phase II and Phase III trials of nivolumab (NIVO) combined with ipilimumab (IPI) in advanced melanoma. Presented at Society for Immunotherapy of Cancer Annual Meeting. National Harbor, MD, USA, 10\u201312 November 2017"},{"issue":"4","key":"1402_CR53","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2217\/imt-2018-0168","volume":"11","author":"A Tarhini","year":"2019","unstructured":"Tarhini A, McDermott D, Ambavane A, Gupte-Singh K, Aponte-Ribero V, Ritchings C, Benedict A, Rao S, Regan MM, Atkins M. Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma. Immunotherapy. 2019;11(4):283\u201395. https:\/\/doi.org\/10.2217\/imt-2018-0168.","journal-title":"Immunotherapy"},{"issue":"6","key":"1402_CR54","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2217\/fon-2020-0643","volume":"17","author":"AC Pavlick","year":"2021","unstructured":"Pavlick AC, Zhao R, Lee CH, Ritchings C, Rao S. First-line immunotherapy versus targeted therapy in patients with BRAF-mutant advanced melanoma: a real-world analysis. Future Oncol. 2021;17(6):689\u201399. https:\/\/doi.org\/10.2217\/fon-2020-0643.","journal-title":"Future Oncol"},{"issue":"16_suppl","key":"1402_CR55","doi-asserted-by":"publisher","first-page":"9540","DOI":"10.1200\/JCO.2022.40.16_suppl.9540","volume":"40","author":"M Weichenthal","year":"2022","unstructured":"Weichenthal M, Svane IM, Sekulovic LK, Mangana J, Mohr P, Marquez-Rodas I, Chmidt H, Ziogas DC, Bender M, Ellebaek E, Urch K, Shalamanova-Deleva G, Gavrilova I, Espinosa E, Dummer R, Rutkowski P, Ascierto PA, Gogas H, Schadendorf D, Bastholt L, EUMelaReg Consortium. EMRseq: registry-based outcome analysis on 1,000 patients with BRAF V600-mutated metastatic melanoma in Europe treated with either immune checkpoint or BRAF-\/MEK inhibition. J Clin Oncol. 2022;40(16_suppl):9540\u20139540.","journal-title":"J Clin Oncol"},{"key":"1402_CR56","unstructured":"Immunotherapy with ipilimumab and nivolumab preceded or not by a targeted therapy with encorafenib and binimetinib (EBIN). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03235245"},{"key":"1402_CR57","unstructured":"Evaluating the efficacy and safety of a sequencing schedule of cobimetinib plus vemurafenib followed by immunotherapy with an anti-PD-L1 antibody in patients with unresectable or metastatic BRAF V600 mutant melanoma (ImmunoCobiVem). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02902029"},{"issue":"16_suppl","key":"1402_CR58","doi-asserted-by":"publisher","first-page":"9548","DOI":"10.1200\/JCO.2022.40.16_suppl.9548","volume":"40","author":"D Schadendorf","year":"2022","unstructured":"Schadendorf D, Gogas H, Sekulovic LK, Meier FE, Eigentler T, Simon JC, Andres P, Terheyden M, Gesierich AH, Herbst RA, K\u00e4hler KC, Ziogas DC, Mijuskovic Z, Garzarolli M, Garbe C, Roesch A, Ugurel S, Gutzmer R, Grob JJ, Zimmer J, Livingstone E. Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAFV600-positive melanoma: Interim analysis of the ImmunoCobiVem study. J Clin Oncol. 2022;40(16_suppl):9548.","journal-title":"J Clin Oncol"},{"key":"1402_CR59","unstructured":"Induction therapy with vemurafenib and cobimetinib to optimize nivolumab and ipilimumab therapy (COWBOY). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02968303"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-023-01402-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-023-01402-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-023-01402-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T07:31:40Z","timestamp":1683358300000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-023-01402-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1402"],"URL":"https:\/\/doi.org\/10.1007\/s11912-023-01402-8","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,30]]},"assertion":[{"value":"7 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Eleonora Cioli and Francesca Sparano declare no conflict of interest. Claudia Trojaniello has participated to Sanofi Advisory Board and has received compensation. Paolo Antonio Ascierto has received grants from Bristol Myers Squibb, Roche-Genentech, Pfizer\/Array, and Sanofi, consulting fees from Bristol Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Merck Serono, Pierre-Fabre, Sun Pharma, Sanofi, Idera, Sandoz, 4SC, Italfarmaco, Nektar, Pfizer\/Array, Lunaphore, Medicenna, Bio-Al Health, ValoTx, Replimmune, and Bayer, and support for attending meetings and travel from Pfizer, Bio-Al Health, and Replimmune and has participated on a Data Safety Monitoring Board or Advisory Board for Bristol Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, AstraZeneca, Immunocore, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Oncosec, Nouscom, Seagen, and iTeos.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}